ECSP10010716A - Combinaciones farmaceuticas. - Google Patents

Combinaciones farmaceuticas.

Info

Publication number
ECSP10010716A
ECSP10010716A EC2010010716A ECSP10010716A ECSP10010716A EC SP10010716 A ECSP10010716 A EC SP10010716A EC 2010010716 A EC2010010716 A EC 2010010716A EC SP10010716 A ECSP10010716 A EC SP10010716A EC SP10010716 A ECSP10010716 A EC SP10010716A
Authority
EC
Ecuador
Prior art keywords
involved
treatment
radiotherapy
diseases
pharmaceutical combination
Prior art date
Application number
EC2010010716A
Other languages
English (en)
Inventor
Frank Hilberg
Martin Friedrich Stefanic
Rolf Kaiser
David Shapiro
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40912046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010716(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP10010716A publication Critical patent/ECSP10010716A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica que puede ser útil para el tratamiento de enfermedades en las que está implicada la proliferación celular, en las que está implicada la migración o apoptosis de células de mieloma, en las que está implicada la angiogénesis o en las que está implicada la fibrosis. La invención también se refiere a un método para el tratamiento de dichas enfermedades que comprende la administración simultánea, separada o secuencial de cantidades eficaces de compuestos activos específicos y/o el cotratamiento con radioterapia, en una relación que proporciona un efecto aditivo y sinérgico, y al uso combinado de estos compuestos específicos y/o radioterapia para la fabricación de preparaciones de combinación farmacéuticas correspondientes.
EC2010010716A 2008-06-06 2010-12-23 Combinaciones farmaceuticas. ECSP10010716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08157749 2008-06-06
US7888208P 2008-07-08 2008-07-08

Publications (1)

Publication Number Publication Date
ECSP10010716A true ECSP10010716A (es) 2011-02-28

Family

ID=40912046

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010716A ECSP10010716A (es) 2008-06-06 2010-12-23 Combinaciones farmaceuticas.

Country Status (34)

Country Link
US (5) US20110178099A1 (es)
EP (2) EP2293795B1 (es)
JP (2) JP5993573B2 (es)
KR (1) KR101760657B1 (es)
CN (1) CN102056609B (es)
AR (1) AR072061A1 (es)
AU (1) AU2009254554B2 (es)
CA (1) CA2726644C (es)
CO (1) CO6280488A2 (es)
CY (2) CY1116877T1 (es)
DK (2) DK2293795T3 (es)
EA (1) EA020046B1 (es)
EC (1) ECSP10010716A (es)
ES (2) ES2662824T3 (es)
HK (1) HK1152640A1 (es)
HR (2) HRP20151186T1 (es)
HU (2) HUE025821T2 (es)
IL (1) IL208953B (es)
LT (1) LT2985025T (es)
MA (1) MA32384B1 (es)
ME (1) ME02273B (es)
MX (1) MX338047B (es)
MY (1) MY158929A (es)
NZ (1) NZ588957A (es)
PE (1) PE20100084A1 (es)
PL (2) PL2985025T3 (es)
PT (2) PT2985025T (es)
RS (2) RS57035B1 (es)
SI (2) SI2293795T1 (es)
TW (1) TWI447113B (es)
UA (1) UA102258C2 (es)
UY (1) UY31866A (es)
WO (1) WO2009147218A1 (es)
ZA (1) ZA201007594B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
EA029996B1 (ru) * 2008-06-06 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Капсулярная лекарственная форма, содержащая суспензионную композицию производного индолинона
US20140350022A1 (en) * 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
EP3365180B1 (en) * 2015-10-21 2019-12-18 Capsugel Belgium NV Printing process for oral dosage forms

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96531A (en) * 1989-12-11 1995-08-31 Univ Princeton History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them)
WO2001014379A2 (en) * 1999-08-23 2001-03-01 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CA2595573A1 (en) * 2004-01-23 2005-08-04 D. James Koropatnick Methods of treating mesothelioma using an antisense oligonucleotide to thymidylate synthase
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060041013A1 (en) * 2004-08-18 2006-02-23 Brittain Jason E Alanosine formulations and methods of use
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
WO2008021410A2 (en) * 2006-08-14 2008-02-21 Sicor Inc. Highly pure pemetrexed diacid and processes for the preparation thereof

Also Published As

Publication number Publication date
PL2293795T3 (pl) 2016-01-29
US20130237549A1 (en) 2013-09-12
CA2726644C (en) 2018-02-06
JP2015007143A (ja) 2015-01-15
AU2009254554B2 (en) 2015-08-20
PL2985025T3 (pl) 2018-06-29
HUE037291T2 (hu) 2018-08-28
TW201002690A (en) 2010-01-16
ZA201007594B (en) 2011-07-27
SI2293795T1 (sl) 2015-12-31
CA2726644A1 (en) 2009-12-10
IL208953B (en) 2018-03-29
KR20110025172A (ko) 2011-03-09
EA201001853A1 (ru) 2011-06-30
CN102056609A (zh) 2011-05-11
MA32384B1 (fr) 2011-06-01
AR072061A1 (es) 2010-08-04
JP2011522008A (ja) 2011-07-28
KR101760657B1 (ko) 2017-07-24
NZ588957A (en) 2013-03-28
JP5993573B2 (ja) 2016-09-14
EP2985025A1 (en) 2016-02-17
CN102056609B (zh) 2012-12-05
LT2985025T (lt) 2018-04-10
RS54293B1 (en) 2016-02-29
EA020046B1 (ru) 2014-08-29
PT2293795E (pt) 2015-11-17
HK1152640A1 (en) 2012-03-09
US20160250218A1 (en) 2016-09-01
CY1120505T1 (el) 2019-07-10
UY31866A (es) 2010-01-29
ES2662824T3 (es) 2018-04-09
AU2009254554A1 (en) 2009-12-10
WO2009147218A1 (en) 2009-12-10
SI2985025T1 (en) 2018-04-30
EP2293795A1 (en) 2011-03-16
PT2985025T (pt) 2018-03-15
US20150174126A1 (en) 2015-06-25
MX2010012937A (es) 2011-02-25
HRP20180602T1 (hr) 2018-05-18
EP2985025B1 (en) 2018-01-17
US20110178099A1 (en) 2011-07-21
HRP20151186T1 (hr) 2015-12-04
HUE025821T2 (en) 2016-04-28
TWI447113B (zh) 2014-08-01
EP2293795B1 (en) 2015-08-12
ES2552238T3 (es) 2015-11-26
PE20100084A1 (es) 2010-02-05
ME02273B (me) 2016-02-20
MY158929A (en) 2016-11-30
UA102258C2 (en) 2013-06-25
DK2985025T3 (en) 2018-03-19
CY1116877T1 (el) 2017-04-05
CO6280488A2 (es) 2011-05-20
IL208953A0 (en) 2011-01-31
RS57035B1 (sr) 2018-05-31
US20180243308A1 (en) 2018-08-30
DK2293795T3 (en) 2015-10-19
MX338047B (es) 2016-03-31

Similar Documents

Publication Publication Date Title
ECSP056132A (es) Combinaciones para el tratamiento de enfermedades que implican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
ECSP10010716A (es) Combinaciones farmaceuticas.
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
GT201400043A (es) Imidazopiridazinas sustituidas con amino
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
CO7240408A2 (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
CU20130069A7 (es) Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CL2011000306A1 (es) Compuestos derivados de di-alquilamida del acido 7-ciclopentil-2-[5-(piperidin o piperazin sustituido)-piridin-2-il amino]-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico, inhibidores de cdk4; composicion farmaceutica; y su uso para el tratamiento del cancer o la inflamacion.
BR112016000561A8 (pt) compostos terapeuticamente ativos e seus métodos de uso
BR112012023021A2 (pt) compostos de indazol e seus usos
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
UY33598A (es) Imidazopiridazinas sustituidas
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
CR20110596A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
UY35293A (es) Isotiazoles sustituidos con amino
ECSP17038893A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
BR112017018198A2 (pt) inibição da atividade de olig2
UY31325A1 (es) Composiciones y métodos para tratar enfermedades y trastornos inmunologicos e inflamatorios
CR20130488A (es) Derivados de tieno [2,3-d]pirimidina y su uso para tratar arritmia
CL2007001857A1 (es) Compuestos derivados del acido fenil-acetico, inhibidores de cox-2; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, osteoartritis, dolor, entre otras.